After Celgene deal, BMS shoots up pharma market cap rankings

Bristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies by market cap into the top 10, according to a new analysis by GlobalDat

Mixed results for Roche drugs in prostate cancer and COVID-1...

Two eye-catching research projects involving drugs from Roche have produced disappointing trial results, after its prostate cancer drug achieved only one of its targets and its inflammatory

Mereo raises $70m as TIGIT cancer drug progresses in clinic

Mereo BioPharma has raised $70m to develop its next-generation anti-TIGIT cancer checkpoint inhibitor drug. 

FDA clears emergency use of Roche test for COVID-19 'cytokin...

FDA extends review of Novartis' MS drug ofatumumab

The FDA has extended its review of Novartis’ potential multiple sclerosis drug ofatumumab, pushing back a decision on the repurposed cancer drug until September this year. 

Roche’s Tecentriq/Avastin combo gets liver cancer nod

The FDA has approved Roche’s combination of its Tecentriq and Avastin drugs in previously-untreated hepatocellular carcinoma (HCC) – the most common form of liver cancer.